Utilizing detection techniques such as qRT-PCR, immunohistochemistry, Northern blot, and Western blot, studies have revealed that IGFBP7 expression is generally downregulated in hepatocellular carcinoma, melanoma, and lung cancer, while showing an upregulation trend in esophageal cancer. This evidence concerns the gene IGFBP7 and hepatocellular carcinoma.